Article: Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleDifferential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms
AuthorsFung, TK1
Cheung, AMS1
Kwong, YL1
Liang, R1
Leung, AYH1
KeywordsJAK2
Myeloproliferative disease
NOD/SCID mice
Polycythemia vera
Issue Date2010
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukres
CitationLeukemia Research, 2010, v. 34 n. 10, p. 1390-1394 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.leukres.2010.01.028
AbstractWe evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET. © 2010 Elsevier Ltd.
ISSN0145-2126
2011 Impact Factor: 2.923
2011 SCImago Journal Rankings: 0.232
DOIhttp://dx.doi.org/10.1016/j.leukres.2010.01.028
ISI Accession Number IDWOS:000281214700022
Funding AgencyGrant Number
RGCHKU 7488/04M
7520/06M
CRCG (HKU)
HKU
Funding Information:

This work was supported by RGC grant (HKU 7488/04M and 7520/06M), a small project funding from CRCG (HKU) and a grant from the Strategic Research Theme on Cancer Stem Cells from HKU. We were grateful to Dr. Harold K.K. Lee, Associate Consultant and the Haematology Team, Princess Margaret Hospital, Hong Kong, for providing us with the venesection samples from some patients.

ReferencesReferences in Scopus
GrantsA study of normal and deregulated haematopoiesis in zebrafish, with special reference to the role of BMP signaling in haematopoietic stem cell proliferation
DC Field
Value
dc.contributor.authorFung, TK
dc.contributor.authorCheung, AMS
dc.contributor.authorKwong, YL
dc.contributor.authorLiang, R
dc.contributor.authorLeung, AYH
dc.date.accessioned2010-09-29T06:14:01Z
dc.date.available2010-09-29T06:14:01Z
dc.date.issued2010
dc.description.abstractWe evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET. © 2010 Elsevier Ltd.
dc.description.grantA study of normal and deregulated haematopoiesis in zebrafish, with special reference to the role of BMP signaling in haematopoietic stem cell proliferation
dc.description.grantcode9878
dc.description.naturepostprint
dc.identifier.citationLeukemia Research, 2010, v. 34 n. 10, p. 1390-1394 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.leukres.2010.01.028
dc.identifier.citeulike6866170
dc.identifier.doihttp://dx.doi.org/10.1016/j.leukres.2010.01.028
dc.identifier.epage1394
dc.identifier.hkuros173552
dc.identifier.hkuros200896
dc.identifier.isiWOS:000281214700022
Funding AgencyGrant Number
RGCHKU 7488/04M
7520/06M
CRCG (HKU)
HKU
Funding Information:

This work was supported by RGC grant (HKU 7488/04M and 7520/06M), a small project funding from CRCG (HKU) and a grant from the Strategic Research Theme on Cancer Stem Cells from HKU. We were grateful to Dr. Harold K.K. Lee, Associate Consultant and the Haematology Team, Princess Margaret Hospital, Hong Kong, for providing us with the venesection samples from some patients.

dc.identifier.issn0145-2126
2011 Impact Factor: 2.923
2011 SCImago Journal Rankings: 0.232
dc.identifier.issue10
dc.identifier.openurl
dc.identifier.pmid20170959
dc.identifier.scopuseid_2-s2.0-77955984222
dc.identifier.spage1390
dc.identifier.urihttp://hdl.handle.net/10722/123827
dc.identifier.volume34
dc.languageeng
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukres
dc.publisher.placeUnited Kingdom
dc.relation.ispartofLeukemia Research
dc.relation.referencesReferences in Scopus
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subjectJAK2
dc.subjectMyeloproliferative disease
dc.subjectNOD/SCID mice
dc.subjectPolycythemia vera
dc.titleDifferential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong